[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350376-105":59,"doc-detail-350376-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","global-prevalence-of-fgfr2b-protein-overexpression-in-advanced-gastric-cancer-and-gastroesophageal-junction-cancers-pooled-analysis-of-two-bemarituzumab-phase-iii-studies","Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies","","Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression is assessed as an emerging biomarker and therapeutic target in advanced gastric and gastroesophageal junction cancers. A pooled analysis used tumor samples from prescreening for two global phase III bemarituzumab studies. From 7,910 evaluable specimens, prevalence of FGFR2b any 2+/3+ and FGFR2b ≥10% 2+/3+ was estimated with defined IHC criteria and analyzed across patient and sample characteristics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/global-prevalence-of-fgfr2b-protein-overexpression-in-advanced-gastric-cancer-and-gastroesophageal-junction-cancers-pooled-analysis-of-two-bemarituzumab-phase-iii-studies/350376/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/global-prevalence-of-fgfr2b-protein-overexpression-in-advanced-gastric-cancer-and-gastroesophageal-junction-cancers-pooled-analysis-of-two-bemarituzumab-phase-iii-studies/350376.png","ImageObject",300,407,{"name":92,"@type":93},"Stanley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical question does this study address?","Question",{"text":112,"@type":113},"It estimates the global prevalence of FGFR2b protein overexpression in advanced gastric and gastroesophageal junction cancers using a validated immunohistochemistry assay.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was FGFR2b overexpression defined and measured?",{"text":117,"@type":113},"FGFR2b overexpression was determined by immunohistochemistry as moderate-to-strong membrane staining (2+ to 3+) in specified proportions of tumor cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What prevalence rates were reported for FGFR2b overexpression?",{"text":121,"@type":113},"The pooled estimates were 36.5% for FGFR2b any 2+/3+ and 16.6% for FGFR2b ≥10% 2+/3+ among 7,910 evaluable samples.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350376,1790145894,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","ORIGINAL ARTICLE  \nGlobal prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies  \nS. B. Maron1 ∗, R.-H. Xu2, Z. A. Wainberg3, S. Y. Rha4, Y. Zhang5, F. Pietrantonio6, S. C. S. Oliveira7, Y. Li8, M.-H. Chen9,  \nK. Korphaisarn10, E. Elimova11, C. A. Calderon12, F. V. Herpe13, 14, W. P. Yong15, T. M. Dos Santos16, M. Tan17, K. Isse16,  \nR. E. Yanes16 & K. Shitara18  \n1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; 2Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangdong, China; 3Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, USA; 4Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; 5Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China; 6Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 7Department of Medical Oncology, Liga Norte-Riograndense Contra O Cancer, Natal, Brazil; 8Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, China; 9Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; 10Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 11Department of Medicine, Princess Margaret Cancer Centre, Toronto, Canada; 12Department of Oncology, Fundacion Cardiovascular de Colombia, Colombia; 13Gastrointestinal Oncology Department, University Hospitals Gasthuisberg, Leuven; 14University of Leuven, Leuven, Belgium; 15Department of Haematology-Oncology, National University Hospital, Singapore; 16Amgen Inc., Thousand Oaks; 17Amgen Inc., South San Francisco, USA; 18Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan  \nAvailable online xxx  \nBackground: Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression is an emerging biomarker and a potential therapeutic target in gastric and gastroesophageal junction cancers (G/GEJC) . Limited data exist on the global prevalence of FGFR2b overexpression in advanced G/GEJC using a validated assay. We assessed the prevalence of FGFR2b protein overexpression in a pooled analysis of tumor samples collected as part of the prescreening process for two global phase III studies of bemarituzumab as first-line treatment for locally advanced or metastatic G/GEJC.  \nMaterials and methods: As of 20 February 2025, 7910 tumor samples from patients prescreened for enrollment in the FORTITUDE-101 (NCT05052801; n = 3752) and FORTITUDE-102 (NCT05111626; n = 4158) studies were centrally tested for FGFR2b protein overexpression by immunohistochemistry (IHC) and had evaluable results. FGFR2b overexpression was defined as both any percentage (>0%) of tumor cells (TCs) and ≥10% of TCs exhibiting moderate (2+) to strong (3+) membrane staining of FGFR2b. Prevalence was analyzed across defined patient and sample characteristics.  \nResults: The estimated prevalence of FGFR2b any 2+/3+ was 36.5%[95% confidence interval (CI) 35.4-37.6; 2887/ 7910] and that of FGFR2b ≥10% 2+/3+ was 16.6%(95% CI 15.7-17.4; 1310/7910) . Prevalence estimates from this pooled analysis and a separate analysis for FORTITUDE-102 [any 2+/3+: 35.8%(95% CI 34.3-37. 2); FGFR2b ≥10% 2+/3+: 17.3%(95% CI 16.1-18.4)] were consistent with results previously reported for FORTITUDE-101 (Rha SY, Zhang Y, Elme A, et al. Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial. JCO Precis Oncol. 2025;9:e2400710) . FGFR2b prevalence was consistent across patient and sample characteristics [age, sex, collection method (biopsy versus resection), collection site, location of primary tumor, and geographic region] .  \nConclusion: T","cbCaiiOqFSxlxB2j","https://ap.wps.com/l/cbCaiiOqFSxlxB2j","pdf",10179911,"English","# Background\n# Materials and methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What clinical question does this study address?\",\"answer\":\"It estimates the global prevalence of FGFR2b protein overexpression in advanced gastric and gastroesophageal junction cancers using a validated immunohistochemistry assay.\"},{\"question\":\"How was FGFR2b overexpression defined and measured?\",\"answer\":\"FGFR2b overexpression was determined by immunohistochemistry as moderate-to-strong membrane staining (2+ to 3+) in specified proportions of tumor cells.\"},{\"question\":\"What prevalence rates were reported for FGFR2b overexpression?\",\"answer\":\"The pooled estimates were 36.5% for FGFR2b any 2+/3+ and 16.6% for FGFR2b ≥10% 2+/3+ among 7,910 evaluable samples.\"}]","Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies | PDF",1790088770,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f1a7f4e8dd58784d56f56f5c5ef0724.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81f9f9a3e9d3032083a486fdba22d16c.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/095a1a42917c6f8f629ade8fb82b543a.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/120ef1c4e6c481a14bd389a4415112f0.webp",980,1265]